Jump to:
Oxford Nanopore Technologies PLC Fundamentals
| Company Name | Oxford Nanopore Technologies PLC | Last Updated | 2024-05-08 |
|---|
| Industry | Biotechnology | Sector | Healthcare |
|---|
| Shares in Issue | 862.586 m | Market Cap | £988.52 m |
|---|
| PE Ratio | 0.00 | Dividend per Share | 0 |
|---|
| Dividend Yield | 0 | Dividend Cover | 0 |
|---|
| EPS | -£0.19 | EPS Growth (%) | 0 |
|---|
| PEG | 0 | DPS Growth (%) | 0 |
|---|
| Debt Ratio | 0.0536 | Debt Equity Ratio | 0.0580 |
|---|
| Asset Equity Ratio | 1.2069 | Cash Equity Ratio | 0.4194 |
|---|
| Quick Ratio | 3.5020 | Current Ratio | 5.01 |
|---|
| Price To Book Value | 1.4885 | ROCE | 0 |
|---|
Oxford Nanopore Technologies PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Oxford Nanopore Technologies PLC Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|
| Tangible Assets | £82.42 m | £63.20 m | £61.92 m |
| Intangible Assets | £32.91 m | £30.04 m | £23.00 m |
| Investments | £209.07 m | £84.97 m | £257,000.00 |
| Total Fixed Assets | £329.88 m | £185.89 m | £91.26 m |
| Stocks | £101.55 m | £87.70 m | £63.07 m |
| Debtors | £42.33 m | £46.97 m | £41.34 m |
| Cash & Equivalents | £270.05 m | £476.19 m | £618.47 m |
| Other Assets | £5.49 m | £7.68 m | £6.08 m |
| Total Assets | £777.06 m | £823.89 m | £841.87 m |
| Liabilities | 2023 | 2022 | 2021 |
|---|
| Creditors within 1 year | £89.20 m | £91.54 m | £105.05 m |
| Creditors after 1 year | £44.01 m | £38.80 m | £32.84 m |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £133.21 m | £130.33 m | £137.89 m |
| Net assets | £643.85 m | £693.56 m | £703.98 m |
| Equity | 2023 | 2022 | 2021 |
|---|
| Called up share capital | £86,000.00 | £83,000.00 | £82,000.00 |
| Share Premium | £698.55 m | £627.56 m | £623.76 m |
| Profit / Loss | -£149.77 m | -£83.41 m | -£166.00 m |
| Other Equity | £643.85 m | £693.56 m | £703.98 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | £643.85 m | £693.56 m | £703.98 m |
| Ratios | 2023 | 2022 | 2021 |
|---|
| Debt Ratio | £0.05 | £0.04 | £0.03 |
| Debt-to-Equity | £0.06 | £0.04 | £0.03 |
| Assets / Equity | 1.2069 | 1.2069 | 1.2069 |
| Cash / Equity | 0.4194 | 0.4194 | 0.4194 |
| EPS | -£0.19 | -£0.12 | -£0.23 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|
| Cash from operating activities | -£137.30 m | -£63.83 m | -£53.20 m |
| Cashflow before financing | -£72.57 m | -£77.54 m | £569.70 m |
| Increase in Cash | -£134.36 m | -£128.90 m | £407.72 m |
| Income | 2023 | 2022 | 2021 |
|---|
| Turnover | £169.67 m | £198.60 m | £133.66 m |
| Cost of sales | £79.19 m | £74.79 m | £60.47 m |
| Gross Profit | £90.48 m | £123.81 m | £73.19 m |
| Operating Profit | -£168.61 m | -£98.48 m | -£164.53 m |
| Pre-Tax profit | -£149.77 m | -£83.41 m | -£166.00 m |
Oxford Nanopore Technologies PLC Company Background
| Sector | Healthcare |
|---|
| Activities | Oxford Nanopore Technologies PLC makes a novel generation of DNA/RNA sequencing technology that provides rich data and is fast, accessible, and easy to use. The Group is primarily involved in researching, developing, manufacturing, and commercializing the world's only commercial nanopore-based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). This enables our customers to perform scientific/biomedical research ina range of areas, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science. |
|---|
| Latest Interim Date | 6 Sep 2023 |
|---|
| Latest Fiscal Year End Date | 6 Mar 2024 |
|---|
Oxford Nanopore Technologies PLC Directors
| Appointed | Name | Position |
|---|
| 2024-04-30 | Mr. Adrian Nevil Hennah | Non-Executive Director |
| 2022-04-12 | Mr. Alan John Aubrey | Non-Executive Director |
| 2024-03-07 | Mr. Duncan Eden Tatton-Brown | Non-Executive Director,Chairman |
| 2024-04-30 | Ms. Wendy Becker | Non-Executive Director,Senior Independent Director |
| 2022-06-30 | Mr. Peter Vance Allen | Non-Executive Director,Chairman |
| 2024-04-12 | Mr. Nicholas Patrick Keher | Executive Director,Chief Financial Officer |
| 2024-04-30 | Mrs. Sarah Gordon Wild | Non-Executive Director |
| 2024-04-30 | Dr. Gurdial Sanghera | Executive Director,Chief Executive Officer |
| 2024-04-30 | Mr. Clive Gavin Brown | Executive Director,Chief Technology, Innovation and Product Officer |
| 2024-04-12 | Mr. Timothy Cowper | Executive Director,Chief Financial Officer |
| 2024-04-12 | Dr. James Willcocks | Executive Director,Chief Business Development Officer |
| 2024-05-01 | Ms. Kate Priestman | Non-Executive Director |
Oxford Nanopore Technologies PLC Contact Details
Oxford Nanopore Technologies PLC Advisors
